Related references
Note: Only part of the references are listed.Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long-Term Use of Glucocorticoids
Michael D. George et al.
ARTHRITIS CARE & RESEARCH (2021)
Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study
Beth I. Wallace et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial
Jon T. Giles et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Adverse Effects of Low-Dose Methotrexate A Randomized Trial
Daniel H. Solomon et al.
ANNALS OF INTERNAL MEDICINE (2020)
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis
Alexandre Sepriano et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Moderate Risk of Hepatitis B Virus Reactivation in HBsAg-/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis
Meng Hsuan Kuo et al.
SCIENTIFIC REPORTS (2020)
Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases
Jose L. Pablos et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes
Rebecca H. Haberman et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis A Cohort Study
Michael D. George et al.
ANNALS OF INTERNAL MEDICINE (2020)
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
Andrea Rubbert-Roth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study
Ajinkya Pawar et al.
LANCET RHEUMATOLOGY (2020)
Incidence and Risk of Glucocorticoid-Associated Adverse Effects in Patients With Rheumatoid Arthritis
Jessica C. Wilson et al.
ARTHRITIS CARE & RESEARCH (2019)
Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study
Ajinkya Pawar et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: A systematic review and meta-analysis
Yuhong Shi et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2019)
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis
Katie Bechman et al.
RHEUMATOLOGY (2019)
Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: What do we know after 20 years of rituximab
Daniele Focosi et al.
REVIEWS IN MEDICAL VIROLOGY (2019)
Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden
Kathrine Lederballe Gron et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs
Toshiyuki Watanabe et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2019)
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids
Jeffrey R. Curtis et al.
ARTHRITIS CARE & RESEARCH (2019)
Risk of Infection with Methotrexate Therapy in Inflammatory Diseases: A Systematic Review and Meta-Analysis
Ammar Ibrahim et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Andrew I. Rutherford et al.
RHEUMATOLOGY (2018)
Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids
Jun Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy
Kevin L. Winthrop et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare
Huifeng Yun et al.
ARTHRITIS & RHEUMATOLOGY (2016)
American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
K. Rajender Reddy et al.
GASTROENTEROLOGY (2015)
Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis
Jasvinder A. Singh et al.
LANCET (2015)
Risks of Herpes Zoster in Patients With Rheumatoid Arthritis According to Biologic Disease-Modifying Therapy
Huifeng Yun et al.
ARTHRITIS CARE & RESEARCH (2015)
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
Sofia Ramiro et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Time Trends in Glucocorticoid Use in Rheumatoid Arthritis: Results From a Population-Based Inception Cohort, 1980-1994 Versus 1995-2007
Ashima Makol et al.
ARTHRITIS CARE & RESEARCH (2014)
Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study
Takayuki Katsuyama et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients
Anat Stern et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
Methotrexate for treating rheumatoid arthritis
Maria Angeles Lopez-Olivo et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
Sanne A. A. van Dartel et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Rheumatoid Arthritis Disease Activity and Disability Affect the Risk of Serious Infection Events in RADIUS 1
Arthur Weaver et al.
JOURNAL OF RHEUMATOLOGY (2013)
The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment
Joachim Listing et al.
RHEUMATOLOGY (2013)
Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis
William G. Dixon et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis
Karen Au et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases
Carlos G. Grijalva et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Abatacept for rheumatoid arthritis
Lara Maxwell et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2009)
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists
Jeffrey R. Curtis et al.
ARTHRITIS AND RHEUMATISM (2007)
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists
L Carmona et al.
ARTHRITIS AND RHEUMATISM (2005)
Frequency of infection in patients with rheumatoid arthritis compared with controls - A population-based study
MF Doran et al.
ARTHRITIS AND RHEUMATISM (2002)
Share Paper
